<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482842</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2020LSK-067</org_study_id>
    <nct_id>NCT04482842</nct_id>
  </id_info>
  <brief_title>Gene-guided Warfarin for Anticoagulation Therapy</brief_title>
  <acronym>GWAT</acronym>
  <official_title>Gene-guided Warfarin for Anticoagulation Therapy in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the effect of warfarin gene polymorphism on the effectiveness and
      safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the
      correlation between genetic testing and compliance rate of INR value. It will illustrate the
      significance of gene-guided warfarin for administered dose to anticoagulation therapy in
      patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose
      prediction model suitable for such patients, and provide basis for the personalized
      medication regimen of warfarin in patients with acute ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke recurrence rate, compliance rate of INR value</measure>
    <time_frame>3 months, 6 months and 12 months</time_frame>
    <description>Evaluation and analysis of the stroke recurrence rate and compliance rate of INR value at 3 months, 6 months and 12 months after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Gene-guided Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine use</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gene detection (CYP2C9*3, VKORC1)</intervention_name>
    <description>Warfarin is administered at the recommended dose by detecting CYP2C9*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.</description>
    <arm_group_label>Gene-guided Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Sodium</intervention_name>
    <description>Warfarin is administered at a gene-guided dose or at a regular dose.</description>
    <arm_group_label>Gene-guided Warfarin</arm_group_label>
    <arm_group_label>Routine use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute ischemic stroke aged â‰¥18 years (cardiogenic cerebral embolism
             patients)

          -  Clinicians judge that long-term oral anticoagulation with warfarin is required

          -  No anticoagulation treatment in the past 10 days

          -  Agree to participate in this project

        Exclusion Criteria:

          -  Patients who had a tendency to bleed when taking warfarin

          -  High-risk groups using warfarin anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 19, 2020</study_first_submitted>
  <study_first_submitted_qc>July 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

